Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials
Primary result · Incident atrial arrhythmiaResult — go to the resultOdds ratio 0.85 95% CI 0.75–0.98Authors' conclusion
SGLT2i therapy was associated with an overall lower risk of atrial arrythmia and SCD in patients with type 2 diabetes mellitus and/or HF or chronic kidney disease. However, SGLT2i therapy was not associated with a lower risk of ventricular arrhythmia.
Study context
- Population
- Patients with type 2 diabetes mellitus, heart failure (HF), or chronic kidney disease
- Participants
- 88,704 patients38 randomized controlled trials
- Comparison
- SGLT2i compared with placebo
- SGLT2in = 48,435
- Controln = 40,269reference
Methodological detailsrandom effect model
- Random effect model
Primary result
Incident atrial arrhythmia
Odds ratio
0.85
95% CI 0.75–0.98
P = 0.02
SGLT2i vs control
OR 0.85 (95% CI 0.75–0.98); P = 0.02
As reported in the abstract
Secondary outcomes
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| SCD | 0.72 (0.55–0.94) | P = 0.02 | |
| Ventricular arrhythmia | 1.03 (0.84–1.26) | P = 0.77 | |
| Cardiac arrest | 0.94 (0.72–1.23) | P = 0.67 | |
| 0.512Odds ratio (log scale) |
Mean age
Follow-up duration
- Mean follow-up duration
- 1.6 years
Original publication
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials. JACC Adv. Published 22 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →